P240031/S005: Neuspera Sacral Neuromodulation (SNM) System
FDA’s recorded scope: Approval for extension of the shelf life for the Trial System Kit, Trial Lead Kit, and External Procedural Kit of the Neuspera Trial System
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 4 FDA records to the applicant name Neuspera Medical, Inc.. 3 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 15, 2025 to Aug 21, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code EZW appears in 4 of the 4 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P240031, with 4 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 51 Daggett Dr., San Jose, CA, 95134. Recorded on P240031/S005, decision dated Aug 21, 2026.
Stimulator, Electrical, Implantable, For Incontinence.
FDA’s recorded scope: Approval for extension of the shelf life for the Trial System Kit, Trial Lead Kit, and External Procedural Kit of the Neuspera Trial System
FDA’s recorded scope: approval for the addition of the Neuspera Wearable
FDA’s recorded scope: approval of an alternative supplier for the foreman needle component.
FDA’s recorded scope: approval of the protocol for the post-approval study (PAS) of Neuspera Sacral Neuromodulation System.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Neuspera Sacral Neuromodulation (SNM) SystemP240031/S005 | Neuspera Medical, Inc. | PMA supplement | Aug 21, 2026 | FDA |
Neuspera Sacral Neuromodulation (SNM) SystemP240031/S003 | Neuspera Medical, Inc. | PMA supplement | Apr 21, 2026 | FDA |
Neuspera Sacral Neuromodulation (SNM) SystemP240031/S004 | Neuspera Medical, Inc. | PMA supplement | Apr 3, 2026 | FDA |
Neuspera Sacral Neuromodulation SystemP240031/S001 | Neuspera Medical, Inc. | PMA supplement | Aug 15, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.